Design of peptide oxytocin antagonists with strikingly higher affinities and selectivities for the human oxytocin receptor than atosiban

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Peptide Science

• Publication date

  2005-10-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/psc.667PMID 15880385
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Atosiban for Preterm Labour

  2012cited by this paper
• Conformationally biased analogs of oxytocin.

  2009cited by this paper
• Some pharmacological properties of cyclic and linear analogs obtained by substituting each residue of an oxytocin antagonist with D-tryptophan.

  2009cited by this paper
• Synthesis of methylated phenylalanines via hydrogenolysis of corresponding 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids. Synthesis and biological activity of oxytocin analogs with methylated phenylalanines in position 2.

  2009cited by this paper
• Design and synthesis of potent in vivo antagonists of oxytocin.

  2009cited by this paper
• Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: comparisons with Atosiban.

  2009influential reference
• Synthesis, pharmacological, conformational, and dynamic studies of the potent hormone antagonists [1-penicillamine, 4-threonine]-oxytocin and [1-penicillamine, 2-phenylalanine, 4-threonine]-oxytocin. Conformational and dynamic considerations in the design of antagonists.

  2009cited by this paper
• Update on the controversies of tocolytic therapy for the prevention of preterm birth

  2004cited by this paper
• The Gordian Knot of Developing Tocolytics

  2004cited by this paper
• SSR126768A (4-Chloro-3-[(3R)-(+)-5-chloro-1-(2,4-dimethoxybenzyl)-3-methyl-2- oxo-2,3-dihydro-1H-indol-3-yl]-N-ethyl-N-(3-pyridylmethyl)-benzamide, Hydrochloride): A New Selective and Orally Active Oxytocin Receptor Antagonist for the Prevention of Preterm Labor

  2004cited by this paper
• The analogs of oxytocin and D-homoarginine vasopressin with bulky substituted phenylalanine in position 2

  2004cited by this paper
• Inhibitory Effect of Barusiban and Atosiban on Oxytocin-Induced Contractions of Myometrium From Preterm and Term Pregnant Women

  2004cited by this paper
• Pharmacology of (2S,4Z)-N-[(2S)-2-Hydroxy-2-phenylethyl]-4-(methoxyimino) -1-[(2′-methyl[1,1′-biphenyl]-4-yl)carbonyl]-2-pyrrolidinecarboxamide, a New Potent and Selective Nonpeptide Antagonist of the Oxytocin Receptor

  2003cited by this paper
• Synthesis and biological evaluation of oxytocin analogues containing L-alpha-t-butylglycine [Gly(Bu t)] in positions 8 or 9.

  2003cited by this paper
• Analogues of a potent oxytocin antagonist with truncated c‐terminus or shorter amino acid side chain of the basic amino acid at position 8

  2003cited by this paper
• Improved radiotracing of oxytocin receptor-expressing tumours using the new [111In]-DOTA-Lys8-deamino-vasotocin analogue

  2003cited by this paper
• Strategies to Prevent the Morbidity and Mortality Associated with Prematurity

  2003cited by this paper
• Preterm labour: an overview of current and emerging therapeutics.

  2003cited by this paper
• FE 200 440: a selective oxytocin antagonist on the term‐pregnant human uterus

  2003cited by this paper
• An update on the controversies of tocolytic therapy for the prevention of preterm birth

  2003cited by this paper
• Synthesis and biological evaluation of oxytocin analogues containing l-α-t-butylglycine [Gly(But)] in positions 8 or 9

  2003cited by this paper
• Discovery of new lead for the design of antagonists of human vasopressin(VP)V1b receptor

  2002cited by this paper
• Oxytocin antagonists

  2002cited by this paper
• Synthesis and characterization of fluorescent antagonists and agonists for human oxytocin and vasopressin V(1)(a) receptors.

  2002cited by this paper
• Antagonists of oxytocin featuring replacement with modified β‐mercaptopropionic acids at position 1

  2002cited by this paper
• The oxytocin receptor system: structure, function, and regulation.

  2001cited by this paper
• Design of Oxytocin Antagonists, which are more Selective than Atosiban

  2001influential reference
• An oxytocin receptor antagonist (atosiban) in the treatment of preterm labor: a randomized, double-blind, placebo-controlled trial with tocolytic rescue.

  2000cited by this paper
• The analogs of oxytocin and D-homoarginine vasopressin with bulky substituted phenylalanine in position 2

  2000cited by this paper
• Pharmacologic characterization of the oxytocin receptor in human uterine smooth muscle cells

  2000cited by this paper
• Analogues of Arginine Vasopressin Modified in Position 2 or 3 with Naphthylalanine: Selective Antagonists of Oxytocin In‐vitro

  2000cited by this paper
• Maintenance treatment of preterm labor with the oxytocin antagonist atosiban. The Atosiban PTL-098 Study Group.

  2000cited by this paper
• Endocrine and paracrine regulation of birth at term and preterm.

  2000cited by this paper
• Molecular pharmacology of AVP and OT receptors and therapeutic potential

  1999cited by this paper
• The control of labor.

  1999cited by this paper
• The control of labor.

  1999cited by this paper
• Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women

  1999cited by this paper
• The synthesis of a new class of oxytocin antagonists.

  1999cited by this paper
• SUBSTITUTION OF THE SIDE-CHAIN-CONSTRAINED AMINO ACIDS BETA -METHYL-2', 6'DIMETHYL-4'-METHOXYTYROSINE IN POSITION 2 OF A BICYCLIC OXYTOCIN ANALOGUE PR OVIDES UNIQUE INSIGHTS INTO THE BIOACTIVE TOPOGRAPHY OF OXYTOCIN ANTAGONIST S

  1998cited by this paper
• Structural bases of vasopressin/oxytocin receptor function.

  1998cited by this paper
• pA, A NEW SCALE FOR THE MEASUREMENT OF DRUG ANTAGONISM

  1997cited by this paper
• Mapping Peptide-binding Domains of the Human V1a Vasopressin Receptor with a Photoactivatable Linear Peptide Antagonist*

  1997cited by this paper
• Small molecule ligands for oxytocin and vasopressin receptors

  1997cited by this paper
• Isosteric substitution of Asn5 in antagonists of oxytocin and vasopressin leads to highly selective and potent oxytocin and V1a receptor antagonists: new approaches for the design of potential tocolytics for preterm labor.

  1996cited by this paper
• The role of oxytocin receptors and vasopressin V1a receptors in uterine contractions in rats: implications for tocolytic therapy with oxytocin antagonists.

  1996cited by this paper
• The substitution of one amino acid residue in position 2 of the AVP molecule leads to a very potent antagonist

  1995cited by this paper
• Advances in the design of selective antagonists, potential tocolytics, and radioiodinated ligands for oxytocin receptors.

  1995cited by this paper
• Effects of a D-Cys6/L-Cys6 interchange in nonselective and selective vasopressin and oxytocin antagonists.

  1995cited by this paper
• Characterization of a novel, linear radioiodinated vasopressin antagonist: an excellent radioligand for vasopressin V1a receptors.

  1995cited by this paper
• Characterization of the human oxytocin receptor stably expressed in 293 human embryonic kidney cells.

  1995cited by this paper
• 1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist.

  1995cited by this paper
• Oxytocin antagonists delay the initiation of parturition and prolong its active phase in rats.

  1995cited by this paper
• The analogs of oxytocin and vasopressin with a bulky amino acid in position 2

  1995cited by this paper
• THE 1- AND 2-NAPHTHYLALANINE ANALOGS OF OXYTOCIN AND VASOPRESSIN

  1995cited by this paper
• Enhanced selectivity of oxytocin antagonists containing sarcosine in position 7.

  1994cited by this paper
• 1-((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo [2.2.1]-heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperaz ine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor.

  1994cited by this paper
• Antagonistic Analogs of Oxytocin with Substituted Phenylalanine or Tyrosine in Position 2

  1994cited by this paper
• 1-(((7,7-Dimethyl-2(S)-(2(S)-amino-4-(methylsulfonyl)butyramido) bicyclo(2.2.1)heptan-1(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl) piperazine (L-368,899): An Orally Bioavailable, Non-Peptide Oxytocin Antagonist with Potential Utility for Managing Preterm Labor.

  1994cited by this paper
• Antagonists for the human oxytocin receptor: an in vitro study.

  1994cited by this paper
• Design, synthesis and some uses of receptor-specific agonists and antagonists of vasopressin and oxytocin.

  1993cited by this paper
• Systematic substitution of an oxytocin antagonist with D-amino acids: unexpected high antagonistic potency of the D-Cys6-substituted analogue.

  1993cited by this paper
• Structure-activity studies of a novel bicyclic oxytocin antagonist.

  1992cited by this paper
• Radioligand binding studies reveal marked species differences in the vasopressin V1 receptor of rat, rhesus and human tissues.

  1992cited by this paper
• Analogs of Deamino Carba Oxytocin with Inhibitory Properties; Synthesis and Biological Activities

  1992cited by this paper
• SYNTHESIS AND PROPERTIES OF "HORMONOGENE" AND "INHIBITOROGENE" TYPE OXYTOCIN ANALOGS*

  1992cited by this paper
• Potent V2/V1a vasopressin antagonists with C-terminal ethylenediamine-linked retro-amino acids.

  1992influential reference
• Myometrial oxytocin receptors and prostaglandin in the parturition process in the rat.

  1992cited by this paper
• Design of potent oxytocin antagonists featuring D-tryptophan at position 2.

  1991cited by this paper
• Improvement in potency of an oxytocin antagonist after systematic substitutions with L-tryptophan.

  1991cited by this paper
• A new tocolytic agent: development of an oxytocin antagonist for inhibiting uterine contractions.

  1990cited by this paper
• Synthesis and Biological Activity of Oxytocin Analogues with β-Amino Acids in Position 2.

  1990cited by this paper
• Solid-phase synthesis of 16 potent (selective and nonselective) in vivo antagonists of oxytocin.

  1989cited by this paper
• Oxytocin receptor blockade: a new principle in the treatment of preterm labor?

  1989cited by this paper
• Discovery, development, and some uses of vasopressin and oxytocin antagonists.

  1989cited by this paper
• 125I-labelled d(CH2)5[Tyr(Me)2,Thr4,Tyr-NH2(9)]OVT: a selective oxytocin receptor ligand.

  1988cited by this paper
• Chapter 4 – Structure–Activity Relationships of Neurohypophyseal Peptides

  1987cited by this paper
• Effects of applied load and particle size on the plastoelasticity and tablet strength of some directly compressible powders

  1987cited by this paper
• Long-Acting Oxytocin Antagonists: Effects of 2-D-Stereoisomer Substitution on Antagonistic Potency and Duration of Action 1

  1987cited by this paper
• Synthesis and some pharmacological properties of two new antagonists of oxytocin.

  1987cited by this paper
• Synthetic antagonists of the myometrial response to vasopressin and oxytocin.

  1986cited by this paper
• Design of oxytocin antagonists with prolonged action: potential tocolytic agents for the treatment of preterm labor.

  1986cited by this paper
• Oxytocin analogues with inhibitory properties, containing in position 2 a hydrophobic amino acid of D-configuration

  1985cited by this paper
• Solid phase synthesis

  1985cited by this paper
• Acidolytic Deprotecting Procedures in Peptide Synthesis

  1984influential reference
• Induction of catecholamine-responsive adenylate cyclase in HeLa cells by sodium butyrate. Evidence for a more efficient stimulatory regulatory component.

  1984cited by this paper
• Oxytocin receptors and human parturition: a dual role for oxytocin in the initiation of labor.

  1982cited by this paper
• Synthesis and biological activity of some very hydrophobic superagonist analogues of luteinizing hormone-releasing hormone.

  1982cited by this paper
• The design of effective in vivo antagonists of rat uterus and milk ejection responses to oxytocin.

  1980cited by this paper
• Synthetic antagonists of in vivo responses by the rat uterus to oxytocin.

  1979cited by this paper
• Solid‐phase synthesis of somatostatin and glucagon‐selective analogs in gram quantities

  1978cited by this paper
• Synthesis and biological activity of somatostatin analogues modified at the tryptophan residue.

  1978cited by this paper
• [1-Deaminopenicillamine,4-threonine]oxytocin, a potent inhibitor of oxytocin.

  1978cited by this paper
• The molecular theory of polyelectrolyte solutions with applications to the electrostatic properties of polynucleotides

  1978cited by this paper
• Synthesis and biological activity of tetragastrin analogues modifying the tryptophan residue.

  1977cited by this paper
• [1-Beta-mercapto-beta,beta-pentamethylenepropionic acid]oxytocin, a potent inhibitor of oxytocin.

  1975cited by this paper
• (1-Beta-mercapto-beta,beta-diethylpropionic acid)-8-lysine-vasopressin, a potent inhibitor of 8-lysine-vasopressin and of oxytocin.

  1974cited by this paper
• Trifluoromethanesulphonic acid, as a deprotecting reagent in peptide chemistry

  1974cited by this paper
• Solid-phase synthesis and some pharmacological properties of 4-threonine analogs of vasopressins and vasotocin and of arginine-vasopressin and arginine-vasotocin.

  1973cited by this paper
• Solid-phase synthesis and pressor potency of (1-deamino-9-ethylenediamine)-lysine-vasopressin.

  1973cited by this paper
• Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

  1973cited by this paper

• Effects of oxytocin receptor ligands on anxiogenic-like effect, social avoidance and changes on medial prefrontal cortex oxytocin receptor expression evoked by chronic social defeat stress in rats.

  2025cites this paper
• Vasopressin and oxytocin receptors in GtoPdb v.2025.3

  2025cites this paper
• The oxytocin antagonist cligosiban reduces human prostate contractility: Implications for the treatment of benign prostatic hyperplasia

  2024cites this paper
• Hypothalamic Paraventricular Stimulation Inhibits Nociceptive Wide Dynamic Range Trigeminocervical Complex Cells via Oxytocinergic Transmission

  2024cites this paper
• Six Decades of History of Hypertension Research at the University of Toledo: Highlighting Pioneering Contributions in Biochemistry, Genetics, and Host-Microbiota Interactions

  2022cites this paper
• Oxytocin signaling in the treatment of drug addiction: Therapeutic opportunities and challenges.

  2021cites this paper
• Molecular Aspects and Structure Activity Relationship of Oxytocin Agonists and Antagonist’s Role in Health

  2021cites this paper
• Vasopressin and oxytocin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

  2019cites this paper
• Targeting the Oxytocin System: New Pharmacotherapeutic Approaches.

  2019cites this paper
• Design of Oxytocin Analogs.

  2019cites this paper
• Subtle modifications to oxytocin produce ligands that retain potency and improved selectivity across species

  2017cites this paper
• New, potent, and selective peptidic oxytocin receptor agonists.

  2014cites this paper
• Micelle-bound conformations of neurohypophyseal hormone analogues modified with a Cα-disubstituted residue: NMR and molecular modelling studies

  2013cites this paper
• The Role of Neurotransmitters in Protection against Amyloid-β Toxicity by KiSS-1 Overexpression in SH-SY5Y Neurons

  2013cites this paper
• Hormones, 2. Peptides and Proteins: Hypothalamic–Pituitary and Calcitropic Hormones

  2013cites this paper
• Conformational Preferences of Proline Derivatives Incorporated into Vasopressin Analogues: NMR and Molecular Modelling Studies

  2012cites this paper
• Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics

  2012cites this paper
• Functional Selective Oxytocin-derived Agonists Discriminate between Individual G Protein Family Subtypes*

  2011cites this paper
• Oxytocin in the medial preoptic area facilitates male sexual behavior in the rat.

  2011cites this paper
• Design, synthesis and biological activity of new neurohypophyseal hormones analogues conformationally restricted in the N-terminal part of the molecule. Highly potent OT receptor antagonists

  2011cites this paper
• Desirability function combining metabolic stability and functionality of peptides

  2011cites this paper
• The medicinal chemistry of peptides.

  2009cites this paper
• Impact of the Merrifield solid phase method on the design and synthesis of selective agonists and antagonists of oxytocin and vasopressin: A historical perspective

  2008cites this paper
• Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.

  2008cites this paper
• A vasopressin/oxytocin-related conopeptide with γ-carboxyglutamate at position 8

  2007cites this paper
• A vasopressin/oxytocin-related conopeptide with gamma-carboxyglutamate at position 8.

  2007cites this paper
• Use of a novel and highly selective oxytocin receptor antagonist to characterize uterine contractions in the rat.

  2007cites this paper
• Targeting the oxytocin receptor to relax the myometrium

  2006cites this paper
• Probing the Existence of G Protein-Coupled Receptor Dimers by Positive and Negative Ligand-Dependent Cooperative Binding

  2006cites this paper
• Design and synthesis of potent, highly selective vasopressin hypotensive agonists

  2006cites this paper
• Gonadal steroid modulation of stress-induced hypothalamo-pituitary-adrenal activity and anxiety behavior: role of central oxytocin.

  2006cites this paper